U.S., Oct. 8 -- ClinicalTrials.gov registry received information related to the study (NCT07210515) titled 'Evaluation of IV AMBTX-01 (Neridronate) for Treatment of CRPS Type 1 (CRPS-RISE)' on Sept. 17.
Brief Summary: Phase 3 Trial of AMBTX-01 (neridronate) for Complex Regional Pain Syndrome Type 1
Study Start Date: March, 2026
Study Type: INTERVENTIONAL
Condition:
Complex Regional Pain Syndrome Type I
Intervention:
DRUG: Neridronate
neridronate 100 mg, given as a 2-hour infusion on Days 1, 4, 7, and 10.
DRUG: Placebo
placebo comparator
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Ambros Therapeutics, Inc.
Published by HT Digital Content Services with permission from Health Daily Digest....